BetaGlue Therapeutics and its shareholders are proud to collaborate with Fondazione Policlinico Universitario Agostino Gemelli in the fight against cancer. Our clinical study in locally advanced pancreatic cancer is on-going. Learn more with this video.
EANM Annual Congress
October 17-21, 2026 | Austria Center Vienna
Vienna, Austria
Register interest: info@betaglue.com
ESMO Congress
October 25-27, 2026 | IFEMA Madrid
Madrid, Spain
Register interest: info@betaglue.com
LSI Europe Summit
September 28 – October 2, 2026 | Grand Hyatt Barcelona
Barcelona, Spain
Register interest: info@betaglue.com
CIRSE Annual Congress
September 5-9, 2026 | Bella Center Copenhagen
Copenhagen, Denmark
Register interest: info@betaglue.com
European Society for Medical Oncology
July 1-4, 2026 | ICM
Munich, Germany
Register interest: info@betaglue.com
American Society of Clinical Oncology
May 29-June 2, 2026 | McCormick Place
Chicago (IL), USA & Online
Register interest: info@betaglue.com
Annual Scientific Meeting
11-15 April, 2026 | Metro Toronto Convention Centre
Toronto (ON), Canada
Register interest: info@betaglue.com
LSI USA Summit
March 16-20, 2026 | Monarch Beach
Dana Point (CA), USA
Register interest: info@betaglue.com
World Congress of Interventional Oncology
January 26-27, 2026 | Università Cattolica del Sacro Cuore
Rome, Italy
Register interest: info@betaglue.com
Advancements in the fight against cancer
January 15-17, 2026 | JW Marriott Miami
Miami (FL), USA
Register interest: info@betaglue.com
44th Annual J.P. Morgan
January 12-15, 2026 | Westin St. Francis
San Francisco (CA), USA
Register interest: info@betaglue.com
Milan, December 1st, 2025 (GlobeNewsire) BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining approval from the Italian Ministry of Health to conduct clinical study in Unresectable Locally Advanced…
Read moreMilan, November 12, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumors, announced today…
Read moreMilan, September 22, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid…
Read more
